Crown Bioscience acquires PreClinOmics

Expanding its cardiovascular and metabolic disease portfolio

Crown Bioscience, a US-based drug discovery and development solutions company, has purchased PreClinOmics, an in vivo preclinical company that specialises in early research in cardiovascular and metabolic diseases (CVMD) as well as renal disease.

No financial information has been revealed.

CrownBio says the acquisition adds some of the most relevant CVMD models to replicate human disease to its portfolio.

'The acquisition of PreClinOmics will allow CrownBio to create a centre of excellence in global translational drug development specifically for cardiovascular and metabolic disease,' said Jean-Pierre Wery, President of Crown Bioscience.

'We are confident that the acquisition will ultimately result in greater success in clinical trials and lower the cost of drug development for diseases that produce some of the highest economic costs in the world.'

The drug development industry will now have a single source that offers the best models available in both cardiovascular and metabolic diseases

PreClinOmics was incorporated in Indianapolis, IN, US in 2001. It provides discovery services, analytical services, ADME/PK services, safety/non-GLP toxicology services and genetic models to the pharmaceutical industry.

PreClinOmics’s name will not disappear after the acquisition. Instead, the company will be referred to as PreClinOmics, a Crown Bioscience company.

'We are thrilled to join Crown Bioscience. The drug development industry will now have a single source that offers the best models available in both cardiovascular and metabolic diseases,' said Joseph Pesek, Chief Executive and co-founder of PreClinOmics.

With this acquisition, CrownBio is expanding its global reach as an end-to-end solution for cardiovascular and metabolic disease research, in addition to its existing oncology franchise. PreClinOmics already has cutting-edge technologies that support a broad range of study designs, including metabolic syndrome, obesity, diabetes, cardiovascular, renal and neurology.

Companies